Medical device company Covalon Technologies Ltd. (TSXV: COV) (OTCQX: CVALF) announced on Wednesday that it common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company (DTC). This milestone streamlines trading on the U.S. OTCQX Market by eliminating manual delays and higher cross-border transaction costs, enhancing liquidity and positioning Covalon for greater market visibility among US investors.

DTC eligibility allows most US-based brokerages to facilitate trades in Covalon shares, supporting investor participation and potential share price appreciation.

The company's recent initiatives include the promotion of Kim Crooks to the Board of Directors and the granting of 150,000 stock options under Covalon's Omnibus Long-Term Incentive Plan, approved by the TSX Venture Exchange on 30 May 2025. Options vest over three years and carry an exercise price of USD2.50, expiring five years from the grant date, subject to shareholder approval at the 2026 Annual General Meeting.

Covalon develops advanced medical technologies focused on wound care, vascular access and surgical consumables, with products designed to improve patient outcomes, reduce healthcare-associated infections and protect skin integrity.